Best Life Sciences Companies in Limburg, Netherlands
The 50 best Life Sciences companies in Limburg, Netherlands in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Cristal Therapeutics.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Limburg
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Cristal Therapeutics Provides nanomedicines based ON CriPec platform for cancer and inflammation disorder | $21M | 70 mo ago | 6 | Cristianne Rijcken Founder and CSO | Series B | — | 1 launch |
| 2 | Neuroplast Developer of neuro-regenerative medicines for patients | $16M | 43 mo ago | 29 | Johannes De Munter CEO | Series B | — | — |
| 3 | Fortimedix Platform for single port surgery | $12M | 117 mo ago | 1 | — | Acquired | 17 patents Manufacturing and steering components for endoscopic medical instruments and minimally invasive devices. | — |
| 4 | Corporis Medical Provider of diagnostic and wound closure devices for laparoscopic surgery | $7M | 32 mo ago | 12 | John Marugg CEO | Series B | — | — |
| 5 | EnzyPep Develops peptide synthesis technology | $6M | 129 mo ago | 6 | Peter van Tilburg CEO | Deadpooled | 48 patents Engineered thermostable enzymes for peptide drug synthesis and lactulose bioproduction | — |
| 6 | Matisse Pharmaceuticals Developing therapies to treat life-threatening inflammation | $4M | 31 mo ago | 9 | Kees Groen CEO | Series A | 2 patents Low‑anticoagulant heparin formulations for sepsis prevention and therapy | — |
| 7 | Bioactor Developer of ingredients for dietary supplements, medical nutrition, and functional food | $3M | 169 mo ago | 15 | — | Acquired | 38 patents Nutraceuticals enhancing cognition, sleep, and physical performance using plant-derived compounds | 1 launch · 1 award |
| 8 | TripleMed Developer of medical device for treating aortic aneurysms | $2M | 106 mo ago | — | Tjeerd Homsma CEO | Series A | 11 patents Biocompatible polymer kits for medical device fabrication and tissue engineering. | — |
| 9 | Phenospex Developer of digital plant phenotyping sensors and automated crop analysis | $2M | 97 mo ago | 28 | — | Series A | 20 patents Optical object detection and laser‑triangulation imaging for precise agricultural/industrial sensing | — |
| 10 | Fabpulous Point-of-care diagnostic testing for heart attacks | $2M | 105 mo ago | — | Conor O'Brien CEO | Deadpooled | 22 patents Patents concentrated in computing, sensing & instrumentation | — |
| 11 | Matisse Pharmaceuticals Heparin based therapeutics for severe sepsis and septic shock. | $2M | 116 mo ago | — | Bob Kool CEO | Seed | 2 patents Low‑anticoagulant heparin derivatives for sepsis prevention and treatment | — |
| 12 | OncoLize Developer of injectable drug depots to treat tumors | $2M | 39 mo ago | 5 | Mike De Leeuw Chief Executive Officer & Founder | Seed | — | — |
| 13 | Materiomics Provider of surface design services for cell culture devices | $1M | 128 mo ago | 8 | Jan de Boer Co-Founder & CSO | Deadpooled | 7 patents Micro‑engineered surface topographies that modulate cell physiology and promote endothelialization. | — |
| 14 | BabyWatcher Direct to consumer ultrasound system for imaging the foetus | $1M | 80 mo ago | 6 | — | Seed | — | — |
| 15 | MagnaMedics Magnetic bead-based reagents and kits | $512K | 134 mo ago | 8 | Detlef Muller-Schulte Co-Founder | Deadpooled | 6 patents Magnetic nanoparticle-coated medical instruments for imaging and targeted therapeutic delivery | — |
| 16 | PharmaCell Provider of cell therapy and regenerative medicine CDMO | $504K | 127 mo ago | 75 | — | Acquired | — | — |
| 17 | Isobionics Production of a variety of natural fragrances and flavor compounds by fermentation | $333K | 35 mo ago | 35 | Toine Janssen Founder & CEO | Acquired | 100 patents Microbial biosynthesis and enzymatic oxidation of high-value terpenes and sesquiterpenes. | — |
| 18 | CiMaas Developer of immunotherapeutics for cancer treatment | $313K | 79 mo ago | 9 | Wilfred V Germeraad Co-Founder & COO | Acquired | 7 patents Manufacturing and preparation of mitotically suppressed and mature dendritic cells for cell therapies | — |
| 19 | Dualtpharma Dutch, preclinical pharma developing combination therapies for solid tumors. | $137K | 107 mo ago | — | Patrick De Boer CEO | Deadpooled | — | — |
| 20 | Glanum Diagnostics Provider of ECG diagnosis equipment | $112K | 81 mo ago | 10 | — | Funding Raised | — | — |
| 21 | Xilloc Provider of 3D-printed orthopedic products | $110K | 76 mo ago | 12 | — | Seed | — | 1 job opening · 2 launchs |
Top 12 Life Sciences companies in Limburg
#1
Series B · Maastricht, Limburg · founded 2015 · 12 employees$6.7Mraised▾
Corporis Medical (formerly Health Value Creation) is developing diagnostic and wound closure devices for laparoscopic surgery. It offers a product, Automatic Trocar Closure (ATC) device is a suturing the wounds after laparoscopic surgery. Another product, Anastomotic Perfusion Measurement (APM) Device is a diagnostic tool for preventing anastomotic leakages after bowel surgery.
- Dec 2023Series B$4.3M
- Dec 2019Grant (prize money)$55.3K
- Dec 2017Series A$2.4M
#2
Series B · Geleen, Limburg · founded 2014 · 29 employees$15.8Mraised▾
Developer of neuro-regenerative medicines for patients. The company's lead product Neuro-Cells is an autologous stem cell treatment that aims to reduce irreversible impact and injury to the nerve system.
- Jan 2023Grant (prize money)$187.5K
- Nov 2021Series B$11.5M
- Mar 2021Grant (prize money)$144K
- Feb 2020Series A$4.3M
#3
Series A · Geleen, Limburg · founded 2014 · 9 employees$3.9Mraised▾
Developing therapies to treat life-threatening inflammation. It offer drug pipeline that targets neutralizing extracellular cytotoxic histones for the treatment of inflammationa nd sepsis.
- Jan 2024Series A$3.9M
#4
Series B · Maastricht, Limburg · founded 2011 · 6 employees$21.2Mraised▾
Cristal Therapeutics (formerly Cristal Delivery) is developing the nanomedicines based on its proprietary CriPec platform for cancer and inflammation. The technology platform consists of tunable polymers, biodegradable drug linkers, and targeting ligands that enable the design and development of targeted nanomedicines. Its lead product is CriPec docetaxel for the treatment of solid tumors is in phase 2 trials. The company also has 3 drugs i.e CPC634, CPC205 and CPC879 in proof of concept trials for inflammation and tumors.
- Oct 2020Grant (prize money)$151.3K
- Nov 2017Grant (prize money)$3M
- Aug 2017Grant (prize money)$3M
- Jan 2017Series B$13.7M
#5
Seed · Maastricht, Limburg · founded 2017 · 5 employees$1.7Mraised▾
Developer of injectable drug depots to treat tumors. Through oral medication or intravenous injections, the company employs thin needles or catheters to localize the small drug depot inside the solid tumor. It creates a variety of depots carrying various Chemo-drugs for the brain, as well as pancreatic, prostate, and urinary tract cancers.
- Apr 2023Seed$1.7M
#6
Acquired · Geleen, Limburg · founded 2008 · 35 employees$332.7Kraised▾
Isobionics creates high-quality natural flavor and fragrance products for the food, beverage, flavor, and fragrance market using their proprietary fermentation technology that uses sucrose as starting material to produce a variety of complex natural compounds. The company's products include valencene (a citrus flavor compound), Nootkatone (a component of grapefruit peel, that is responsible for the typical odor and flavor of grapefruit peel oil), beta elemene (a compound found in many plants, but extracted mainly from ginger roots), sandalwood oil, patchouli oil.
- Sep 2023Grant (prize money)$332.7K
- Mar 2014Series C—
- 2008Seed—
#7
Acquired · Nuth, Limburg · founded 1999 · 1 employees$12Mraised▾
Fortimedix provides the Symphonx Surgical Platform which is a single-port surgery solution compatible with a standard 15mm trocar. The symphonX™ Surgical Platform is composed of the symphonX Introducer and Instruments that are used in minimally invasive abdominal laparoscopic surgery. The symphonX Introducer is intended to establish a path of entry for laparoscopic instruments for use during minimally invasive abdominal laparoscopic surgery in combination with the symphonX Instruments. The symphonX Instruments are intended for use in minimally invasive abdominal laparoscopic surgical procedures for grasping, mobilizing, dissecting, retracting, cutting, cauterizing, ligating, and suction/irrigation of tissue and vessels during laparoscopic procedures. The platform is both FDA 510(k) cleared and CE Mark approved. The company plans to commercially launch the product in Europe in 2017.
- Oct 2016Series A$12M
#8
Deadpooled · Geleen, Limburg · founded 2012 · 6 employees$5.5Mraised▾
EnzyPep engages in developing innovative tools for peptide synthesis. The company is focused on new production method for commercial manufacturing of peptides. Lowering cogs, improving product quality, creating improved NCEs and generics. Additionally, the company also offers services in the custom development of enzymes. It jas six approved patents and two in examination phase.
- Nov 2015Series A$5.5M
- 2014Seed—
#9
Series A · Heerlen, Limburg · founded 2010 · 28 employees$2.4Mraised▾
Developer of digital plant phenotyping sensors and automated crop analysis. The company provides tools for plant measurement without integration or manual measuring. It offers sensors, software, and phenotyping applications for herbicide and biostimulant screening. The sensors include multispectral 3D scanners, precision irrigation, and weight data systems. Software analyzes and visualizes plant sensor data, providing full process automation.
- Jul 2018Series A$2.4M
- May 2017Grant (prize money)$61.4K
- Jan 2017Grant (prize money)$59.6K
#10
Deadpooled · Maastricht, Limburg · founded 2008$2Mraised▾
Fabpulous was spun out of Maastricht University at the end of 2008. They have developed a technology that allows a simple and rapid diluted plasma preparation from a drop of blood. Their flagship product is a disposable plasma preparation device that can be integrated with many IVD detection platforms. The first product application is a rapid test for the fatty acid binding protein (H-FABP), to diagnose the risk of heart attacks in a patient exhibiting chest pains.
- Oct 2017Grant (prize money)$1.9M
- Feb 2015Series B$2M
- 2009Seed—
#11
Series A · Maastricht, Limburg · founded 2011$2.4Mraised▾
Developer of minimally invasive products designed to focus on the treatment of aortic aneurysms. The company's products consist of an elastic polymer that fills and cures inside the aneurysm sac, enabling doctors to treat abdominal aortic aneurysms through a percutaneous endovascular procedure rather than open surgery.
#12
Seed · Heerlen, Limburg · founded 2013 · 6 employees$1.2Mraised▾
Babywatcher provides a direct-to-consumer ultrasound imaging system for monitoring foetal development. The company's product consists of a portable ultrasound device, and a cloud-based service for acquiring, storing and review of the images and movies prepared by the user. The company provides the device on rent to the user who then undergoes a short video-based training on the setting up and configuration of the system and the user account. The user can then make short videos and take images of the foetus, and upload them to the cloud-based account for later viewing and review. The company's system is not an accreditated diagnostic device, and is not a replacement for clinical ultrasound imaging. The software does not offer any functionality for conducting measurements and analysis of the images for diagnostic purposes.
- Nov 2019Seed$1.1M
- Jul 2017Seed$113.6K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the Netherlands
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 513 Netherlands-affiliated papers.
- Wageningen University & Research116
- Utrecht University59
- Leiden University Medical Center43
- Netherlands Institute of Ecology35
- Erasmus MC30
- Messenger RNA1→6
- Gene3→7
- DNA damage1→5
- Immune system1→5
- DNA repair1→4
- Gene1→5
- Biological pest control1→4
- Population1→4
- Production (economics)1→5
- Public health1→4
- Food security2→4
- Food safety2→4
Where biotechnology is researched across Netherlands
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.